Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
AbCellera Biologics Inc. (ABCL) had Return on Tangible Equity of -6.83% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$4.05M |
|
$-55.43M |
|
-- |
|
$4.05M |
|
$66.83M |
|
$-62.78M |
|
$3.81M |
|
$-58.97M |
|
$-58.97M |
|
$-55.43M |
|
$-55.43M |
|
$-55.43M |
|
$-55.43M |
|
$-62.78M |
|
$-53.99M |
|
305.56M |
|
305.56M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$679.23M |
|
$416.68M |
|
$628.35M |
|
$1.31B |
|
$53.19M |
|
-- |
|
$358.37M |
|
$411.56M |
|
$896.02M |
|
$811.68M |
|
$896.02M |
|
306.47M |
|
| Cash Flow Statement Financials | |
$-7.60M |
|
$-13.74M |
|
$13.59M |
|
$155.25M |
|
$147.03M |
|
$-8.22M |
|
$24.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.77 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1550.05% |
|
-1550.05% |
|
-- |
|
-1455.93% |
|
-1368.57% |
|
$-13.56M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.22 |
|
413.27 |
|
-6.19% |
|
|
Return on Tangible Equity |
-6.83% |
-4.24% |
|
-6.19% |
|
$2.92 |
|
$-0.04 |
|
$-0.02 |
|